Blog: NEMAURA MEDICAL INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) – Marketscreener.com

Item 7.01. Regulation FD Disclosure.

On January 24, 2023, Nemaura Medical, Inc. (the “Company”) issued a press
release announcing initial results from patient studies of its metabolic health
program Miboko with the National Health Service (NHS) in the United Kingdom.

The information included in this Current Report on Form 8-K, including Exhibit
99.1, shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise
subject to the liabilities of that section, nor shall such information be deemed
incorporated by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set forth by specific
reference in such a filing. The information set forth under this Item 7.01 shall
not be deemed an admission as to the materiality of any information in this
Current Report on Form 8-K that is required to be disclosed solely to satisfy
the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


Exhibit No.     Description

99.1              Press release issued by the registrant on January 24, 2023.
104             Cover Page Interactive Data File - the cover page XBRL tags are
                embedded with the Inline XBRL document

© Edgar Online, source Glimpses